CLOs on the Move

GlycoMimetics

www.glycomimetics.com

 
At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow`s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company`s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details
Christian Dinneen-Long
 Vice President and Corporate Counsel Profile

Similar Companies

Biocompare

Biocompare is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marligen Biosciences

Marligen Biosciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Predictive Diagnostics

Predictive Diagnostics is a Vacaville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seres Health

Seres Health is a clinical-stage therapeutics company focused on discovering and developing Ecobiotic® therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome.  Founded by the Flagship Ventures innovation foundry, VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases. Seres recently announced a research alliance with Mayo Clinic and has received over $20 million in funding to date.

BPGbio

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.